Key facts
- This page summarizes Barry E. Greene's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 21 Jan 2025, 16:11.
Barry E. Greene - 16 Jan 2025 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- SAGE
- Reported as of
- 16 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jan 2025, 16:11:46 UTC
- Prior SEC filing
- 07 Aug 2024
- Next SEC filing
- 11 Apr 2025
- Source filing
- View source filing
- Reporting owner signature
- Brandon Marsh, attorney in fact for GREENE BARRY E.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Barry E. Greene filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 21 Jan 2025.
Change
- Previous filing in this sequence was filed on 07 Aug 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAGE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +174,000
- Change %
- Price
- $0.000000
- Shares after
- 174,000
- Date
- 16 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 174,000
- Exercise price
- $6.97
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The securities awarded on January 16, 2025 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. Options to purchase 43,500 shares of common stock shall vest on the one year anniversary of January 16, 2025, with 130,500 shares vesting in 36 equal monthly installments thereafter.